Neil Stahl - May 14, 2021 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Research and Development
Signature
/s/**Neil Stahl
Stock symbol
REGN
Transactions as of
May 14, 2021
Transactions value $
-$19,359,184
Form type
4
Date filed
5/18/2021, 04:04 PM
Next filing
Dec 6, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Gift $0 -435 -1.76% $0.00 24.3K Feb 25, 2021 Direct
transaction REGN Common Stock Options Exercise $7.17M +40K +164.74% $179.13 64.3K May 14, 2021 Direct
transaction REGN Common Stock Tax liability -$14.4M -27.8K -43.21% $516.69 36.5K May 14, 2021 Direct
transaction REGN Common Stock Options Exercise $650K +12.5K +34.24% $52.03 49K May 14, 2021 Direct
transaction REGN Common Stock Tax liability -$3.72M -7.2K -14.7% $516.69 41.8K May 14, 2021 Direct
transaction REGN Common Stock Sale -$1.75M -3.38K -8.08% $518.63 38.4K May 17, 2021 Direct F1
transaction REGN Common Stock Sale -$5.37M -10.3K -26.9% $519.47 28.1K May 17, 2021 Direct F2
transaction REGN Common Stock Sale -$1.98M -3.81K -13.55% $520.17 24.3K May 17, 2021 Direct F3
holding REGN Common Stock 5.79K May 14, 2021 By 401(k) Plan
holding REGN Common Stock 9.13K May 14, 2021 by 2019 GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -12.5K -100% $0.00* 0 May 14, 2021 Common Stock 12.5K $52.03 Direct F4
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -40K -35.56% $0.00 72.5K May 14, 2021 Common Stock 40K $179.13 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents volume-weighted average price of sales of 3,379 shares of Company stock on May 17, 2021 at prices ranging from $518.02 to $518.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.
F2 Represents volume-weighted average price of sales of 10,336 shares of Company stock on May 17, 2021 at prices ranging from $519.00 to $519.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.
F3 Represents volume-weighted average price of sales of 3,806 shares of Company stock on May 17, 2021 at prices ranging from $520.02 to $520.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2021 at each separate price.
F4 The option became exercisable on December 31, 2014, based upon the satisfaction by the Company of certain performance criteria during the period ended December 31, 2014.
F5 The stock option award vested in four equal annual installments, commencing one year after the date of grant.